These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical study of inhaled corticosteroid in non-asthmatic chronic obstructive pulmonary disease].
    Author: Ouyang R, Yin B.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 1998 Aug; 21(8):497-9. PubMed ID: 11360524.
    Abstract:
    OBJECTIVE: There is less unanimity about the effects of inhaled corticosteroid in patients with non-asthmatic chronic obstructive pulmonary disease(COPD). The aim of this study is to determine whether patients with non-asthmatic COPD have favorable responses to inhaled corticosteroid (ICS). METHOD: A randomized, placebo-controlled, single-blind trial of inhaled beclomethasone dipropionate(BDP 1000 micrograms daily for 6 weeks) was carried out in 61 patients with stable non-asthmatic COPD. Before and after the therapy, the scores of clinical symptoms and the scores of quality of life were recorded, and the pulmonary function and plasma level of endothelin-1 (ET-1) were measured. RESULT: 58 patients finished the study. Compared with the placebo-group, after receiving 6 weeks of ICS therapy, the BDP group showed significant improvement in clinical symptoms (P < 0.05), but not in the quality of life (P > 0.05). There was also an improvement in FEV1(P < 0.001), but not in MMEF (P > 0.05). The plasma concentration of ET-1 was not changed significantly in both groups. CONCLUSION: The study suggested that the therapy of ICS (1000 micrograms daily for 6 weeks) can improve clinical symptoms and pulmonary function in patients with stable non-asthmatic COPD, but cannot affect the quality of life and the plasma concentration of ET-1.
    [Abstract] [Full Text] [Related] [New Search]